Track topics on Twitter Track topics that are important to you
The U.S. Food and Drug Administration on Thursday approved Bristol-Myers Squibb Co's multiple sclerosis (MS) treatment, Zeposia, but its launch will be delayed due to the coronavirus outbreak, the drugmaker said.
Original Article: U.S. FDA approves Bristol-Myers MS drug, coronavirus to delay launchNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...